
Please try another search
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Kaimin Chu | - | - | Chairman & CEO |
Tsung-Chih Chiu | - | 2022 | Independent Director |
Yoa-Pu Hu | - | - | Member of Scientific Advisory Board |
Li-Chun Han | 67 | 2022 | Independent Director |
Shou-Dong Lee | - | - | Member of Scientific Advisory Board |
Wei-Chao Chen | - | - | Member of Scientific Advisory Board |
Shan-Tai Ho | - | - | Member of Scientific Advisory Board |
Pao-Lin Ma | 63 | 2022 | Representative Director |
Ming-Chien Kao | - | 2022 | Independent Director |
Hsing Yu Lin | - | 2022 | Director |
Cheng-Hui Hsiung | - | 2022 | Chief Operating Officer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review